Provider QP12-23 Change in Prior Authorization Process for Experimental or Investigative Services Read More
Provider QP6-23 Commercial Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Rebyota™, and Sunlenca® Injection Read More
Provider QP7-23 MHCP Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Lunsumio™, Rebyota™, Sunlenca® Injection, and Vivimusta Read More
Provider QP8-23 Commercial Formulary Addition for Growth Hormone Therapeutic Class: Genotropin® (somatropin) Read More
Provider P77R1-22 Update: New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective January 30, 2023 Read More
Provider P6-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Sleep Management Clinical Guideline Updates Read More
